MedTrace Logo

A Phase III Long-term Study of TAK-536TCH in Participants With Essential Hypertension

NCT02277691 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 341

Last updated 2017-08-02

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety of long-term administration of TAK-536, amlodipine (AML), and hydrochlorothiazide (HCTZ) in participants with essential hypertension.

Conditions

  • Essential Hypertension

Interventions

DRUG

TAK-536TCH tablet

TAK-536TCH tablets

DRUG

TAK-536CCB tablet

TAK-536CCB tablets

DRUG

HCTZ 12.5 mg tablet

HCTZ tablets

Sponsors & Collaborators

Principal Investigators

  • Medical Director Clinical Science · Takeda

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-07
Primary Completion
2016-04-25
Completion
2016-04-25

Countries

  • Japan

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02277691 on ClinicalTrials.gov